Thermo Fisher Scientific has acquired a 9 percent stake in Calculus portfolio company Yourgene Health by exercising warrants it held in the molecular diagnostics company.
Under the terms of the agreement, Yourgene will exclusively promote its noninvasive prenatal testing products on Thermo Fisher’s Ion Torrent next-generation sequencing systems in the Southeast Asia markets for three years. Yourgene, formerly known as Premaitha Health, is headquartered in Manchester, UK, but also has offices in Taiwan and Singapore.
Lyn Rees, Yourgene CEO, said in a statement that the agreement will enable the company to “enter the new financial year effectively debt free, with no distractions from litigation, and with a strengthened leadership team that is aligned to deliver a platform-agnostic business both within NIPT and the wider genetic testing market.”
Rees added that the company has “a strong pipeline of new product opportunities that will broaden our offering, making Yourgene even more relevant to our global partners.”